Background The PAILOT trial was a randomized controlled trial aimed to evaluate proactive
vs reactive therapeutic drug monitoring in children with Crohn's disease (CD) treated with …

Summary Background In the IMAgINE 1 study, adalimumab induced and maintained
remission of moderate‐to‐severe Crohn's disease in children. Aim To assess the efficacy …

METHODS: Among 100 patients, 75 met the inclusion criteria, and 62 were matched by
propensity score. We evaluated time to treatment escalation as the primary outcome and …

BACKGROUND & AIMS: The IMAgINE 1 study (NCT00409682) evaluated the safety and
efficacy of adalimumab double-blind maintenance dosing regimens following open-label …

Objectives: European Crohn's Colitis Organization (ECCO) and the European Society of
Pediatric Gastroenterology, Hepatology and Nutrition (ESPGHAN) guidelines recommend …

Objectives: Adalimumab has recently become available for adult patients with Crohn
disease (CD) as a viable alternative tumor necrosis factor-α inhibitor to infliximab. To our …

Abstract Information on safety and efficacy of adalimumab in children with Crohn's disease
(CD) is limited. We present a case-series of 14 children with severe CD treated with …

Abstract Background and Aim: Adalimumab is well-established therapy for adults with
Crohn's disease [CD]. The aim of the study was to systematically assess the published …

Objectives: Adalimumab, a humanised anti‐tumour necrosis factor antibody, is an effective
treatment in adult patients with refractory Crohn disease (CD). The available literature on its …

OBJECTIVES: Adalimumab, an anti-tumor necrosis factor immunoglobulin-1 antibody, is
increasingly being reported as a potential treatment option for children with moderate-to …